Trou­bled Teva's suc­ces­sor to Co­pax­one just failed a big PhI­II test for mul­ti­ple scle­ro­sis

Af­ter years of set­backs, de­lays and sundry frus­tra­tions, a deeply trou­bled Te­va says that a late-stage tri­al for laquin­i­mod — long billed as a suc­ces­sor to the ag­ing flag­ship ther­a­py Co­pax­one for mul­ti­ple scle­ro­sis — failed the test on the re­laps­ing-re­mit­ting form of the dis­ease.

Te­va’s drug — her­ald­ed as its bright­est pipeline prospect — did not meet the pri­ma­ry end­point, try­ing to sig­nif­i­cant­ly im­prove the time to dis­abil­i­ty pro­gres­sion com­pared to place­bo af­ter three months.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER